Ronald J. Daniels - 06 Nov 2025 Form 4 Insider Report for BridgeBio Pharma, Inc. (BBIO)

Role
Director
Signature
/s/ Will Solis, Attorney-in-Fact
Issuer symbol
BBIO
Transactions as of
06 Nov 2025
Net transactions value
-$1,774,275
Form type
4
Filing time
07 Nov 2025, 18:03:37 UTC
Previous filing
24 Jun 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
DANIELS RONALD J Director C/O BRIDGEBIO PHARMA, INC., 3160 PORTER DR., SUITE 250, PALO ALTO /s/ Will Solis, Attorney-in-Fact 07 Nov 2025 0001164475

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BBIO Common Stock Options Exercise $2,114,724 +61,031 +359% $34.65 78,022 06 Nov 2025 Direct
transaction BBIO Common Stock Sale $3,888,999 -61,031 -78% $63.72 16,991 06 Nov 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BBIO Stock Option (Right to Buy) Options Exercise $0 -61,031 -67% $0.000000 30,523 06 Nov 2025 Common Stock 61,031 $34.65 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the weighted average sale price of the shares sold from $63.70 to $63.88 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
F2 The shares subject to this option vested and became exercisable in three annual installments from February 12, 2020 to February 12, 2023.

Remarks:

Exhibit 24 - Power of Attorney